Kyverna Therapeutics, Inc.(KYTX:US)
Market Cap$361.38M
Key Metrics
Price$5.97
Revenue (TTM)$0
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$156.4M
EBITDA (TTM)-$153.62M
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$32.19M
Total Assets$257.02M
Net Assets$195.58M
Total Debt$33.76M
Key Metrics
Price$5.97
Revenue (TTM)$0
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$156.4M
EBITDA (TTM)-$153.62M
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$32.19M
Total Assets$257.02M
Net Assets$195.58M
Total Debt$33.76M
Financials
| Name | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $282K |
Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| $41.37M | $39.28M | $38.73M | $44.41M | $47.41M | $41.04M | $38.77M | $33.44M | $29.36M | $21.38M | $16.28M | $13.3M | $11.45M | $9.06M | |
| Research and Development | $30.07M | $30.01M | $30.46M | $35.82M | $37.43M | $33.48M | $29.19M | $27.32M | $22.48M | $17.16M | $13.64M | $10.41M | $8.71M | $7.07M |
| Selling, General, and Administrative | $11.29M | $9.27M | $8.27M | $8.59M | $9.98M | $7.56M | $9.58M | $6.11M | $6.88M | $4.21M | $2.64M | $2.9M | $2.73M | $1.99M |
| Other Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income | -$41.37M | -$39.28M | -$38.73M | -$44.41M | -$47.41M | -$41.04M | -$38.77M | -$33.44M | -$29.36M | -$21.38M | -$16.28M | -$13.3M | -$11.45M | -$8.78M |
| $1.64M | $1.48M | $1.94M | $2.33M | $2.77M | $3.55M | $4.28M | $4.63M | $2.67M | $710K | $817K | $211K | $302K | $279K | |
| Non-Operating Interest Income | $2.33M | $1.91M | $2M | $2.36M | $2.83M | $3.58M | $4.36M | $4.69M | $2.74M | $789K | $880K | $264K | $349K | $297K |
| Non-Operating Interest Expense | $667K | $444K | $7K | $14K | $25K | $27K | $32K | $39K | $44K | $47K | $50K | $46K | $44K | $41K |
| Other Income/Expense | -$21K | $17K | -$53K | -$21K | -$27K | $4K | -$45K | -$23K | -$26K | -$32K | -$13K | -$7K | -$3K | $23K |
Income Before Tax | -$39.73M | -$37.8M | -$36.79M | -$42.08M | -$44.64M | -$37.49M | -$34.49M | -$28.8M | -$26.69M | -$20.67M | -$15.47M | -$13.09M | -$11.14M | -$8.5M |
Income Tax | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -$39.73M | -$37.8M | -$36.79M | -$42.08M | -$44.64M | -$37.49M | -$34.49M | -$28.8M | -$26.69M | -$20.67M | -$15.47M | -$13.09M | -$11.14M | -$8.5M |
Minority Interests | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income to Common | -$39.73M | -$37.8M | -$36.79M | -$42.08M | -$44.64M | -$37.49M | -$34.49M | -$28.8M | -$26.69M | -$20.67M | -$15.47M | -$13.09M | -$11.14M | -$8.5M |
Shares Outstanding (Basic) | 60.43M | 47.16M | 43.42M | 43.23M | 43.22M | - | 43.16M | 43.13M | 23.75M | - | 40.82M | 40.82M | 25.8M | - |
Shares Outstanding (Diluted) | 60.43M | 47.16M | 43.42M | 43.23M | 43.22M | - | 43.16M | 43.13M | 23.75M | - | 40.82M | 40.82M | 25.8M | - |
EPS (Basic) | -$0.66 | -$0.80 | -$0.85 | -$0.97 | -$1.03 | - | -$0.80 | -$0.67 | -$1.12 | - | -$0.38 | -$0.32 | -$0.43 | - |
EPS (Diluted) | -$0.66 | -$0.80 | -$0.85 | -$0.97 | -$1.03 | - | -$0.80 | -$0.67 | -$1.12 | - | -$0.38 | -$0.32 | -$0.43 | - |
EBIT | -$39.06M | -$37.36M | -$36.78M | -$42.07M | -$44.61M | -$37.46M | -$34.46M | -$28.76M | -$26.65M | -$20.62M | -$15.42M | -$13.05M | -$11.1M | -$8.46M |
EBITDA | -$38.71M | -$36.99M | -$36.37M | -$41.55M | -$44.11M | -$36.9M | -$33.9M | -$28.23M | -$26.17M | -$20.16M | -$14.98M | -$12.63M | -$10.71M | -$8.08M |